Arcutis Biotherapeutics Inc (ARQT) 뉴스

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Form 144 - Report of proposed sale of securities

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

New patient-reported outcome data from INTEGUMENT-1 and -2 demonstrate that ZORYVE cream 0.15% rapidly...

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Quarterly investor conference call and webcast is scheduled for Wednesday, November 6 at 4:30 p.m. ETArcutis...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action...